What is CVE-2015-3965?

CVE-2015-3965 is a high-severity vulnerability in Hospira Symbiq Infusion System, classified under CWE-264. CVSS score: 8.8/10. Published 2019-03-23.

How severe is CVE-2015-3965?

High severity. CVSS v3 base score is 8.8 out of 10.

Vulnerability in Hospira Symbiq Infusion System

CVE-2015-3965

Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.

EPSS: 0.029 (85.4th percentile) — read the EPSS interpretation.

CVSS v3 metric

CVSS v3 base score 8.8 (High). Vector: CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H.

Affected products

Hospira Symbiq Infusion System — versions 3.13 and earlier
Pfizer Symbiq_infusion_system
Pfizer Symbiq_infusion_system_firmware

Weakness classification (CWE)

CWE-264

References

ics-cert@hq.dhs.gov (US Government Resource, Third Party Advisory, x_refsource_MISC)

Frequently asked questions

What is CVE-2015-3965?: CVE-2015-3965 is a high-severity vulnerability in Hospira Symbiq Infusion System, classified under CWE-264. CVSS score: 8.8/10. Published 2019-03-23.
How severe is CVE-2015-3965?: High severity. CVSS v3 base score is 8.8 out of 10.